{"id":20262,"date":"2025-03-21T02:42:48","date_gmt":"2025-03-21T02:42:48","guid":{"rendered":"https:\/\/www.hotelsalepage.com\/feed\/cision-pr-newswire\/seegene-unveils-hpv-genotyping-solution-at-eurogin-2025\/"},"modified":"2025-03-21T02:42:48","modified_gmt":"2025-03-21T02:42:48","slug":"seegene-unveils-hpv-genotyping-solution-at-eurogin-2025","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=20262","title":{"rendered":"Seegene Unveils HPV Genotyping Solution at EUROGIN 2025"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

–\u00a0\u00a0\u00a0 Presented a roadmap to enhance screening reliability at the world’s leading multidisciplinary HPV congress held in Portugal<\/span> from March 16-19<\/span>
–\u00a0\u00a0\u00a0 Demonstrated how self-collected samples for HPV testing can bridge gaps in cervical cancer screening and advance HPV screening goals<\/p>\n

SEOUL, South Korea<\/span><\/span>, March 20, 2025<\/span><\/span> \/PRNewswire\/ — Seegene Inc., a global leader in total solution for PCR molecular diagnostics, presented its high-precision Human Papillomavirus (HPV) screening and full genotyping solutions at the European Research Organization on Genital Infection and Neoplasia (EUROGIN) 2025 in Porto, Portugal<\/span> from March 16-19<\/span>.<\/p>\n

\n

\"Seegene <\/a>
Seegene showcases its flagship HPV diagnostic product lineup and presents its HPV genotyping solution at EUROGIN 2025 in Portugal from March 16-19 (CET).<\/span><\/p>\n<\/div>\n

The company showcased its expertise through an exhibition booth under the theme “Elevating Confidence in HPV Screening” and hosted symposium programs to emphasize accurate identification of high-risk HPV types related to cervical cancer is critical. Seegene’s advanced solution enhances diagnostic accuracy, enabling timely and effective detection.<\/p>\n

Seegene presented its flagship HPV diagnostic product lineup that are designed to simultaneously detect HPV genotypes responsible for cervical cancer and\/or HPV-related cancer. This capability is crucial in identifying high-risk HPV types that are known to cause cervical cancer and detecting other genotypes that are associated with benign tumors.<\/p>\n

At the Seegene symposium on March 16<\/span>, leading clinical experts from Europe<\/span> discussed strategies for integrating HPV testing into real-world clinical practice. The symposium underscored the critical role of HPV testing in the early detection of cervical cancer. Additionally, the experts highlighted the advantages of self-sampling, a method that enables individuals to collect their own samples. This approach not only streamlines the testing process but also promotes the broader adoption of HPV screening.<\/p>\n

“Seegene’s HPV testing solutions are designed to deliver accurate diagnostics and reliable testing capabilities in real-world clinical environments,” said Daniel Shin<\/span>, Executive Vice President and Chief Global Sales & Marketing Officer at Seegene.<\/p>\n

Seegene’s annual participation in EUROGIN is a testament to its commitment to advancing HPV screening and genotyping for the accurate diagnosis and prevention of cervical cancer. In July 2024<\/span>, the company also took part in the Asia-Oceania Research Organization on Genital Infection and Neoplasia (AOGIN) 2024 held in Seoul<\/span>.<\/p>\n

According to the World Health Organization (WHO), Cervical cancer is the fourth most common cancer among women worldwide and the second leading cause of cancer-related deaths. In 2018, the WHO launched the 90-70-90 campaign to eliminate cervical cancer. The targets aim to achieve 90% HPV vaccination coverage among girls by the age of 15; 70% of women screened using high-performance tests by the age of 35 and 45; and treatment for 90% of women identified with pre-cancer and invasive cancer by 2030.<\/p>\n

About Seegene<\/b><\/p>\n

Seegene has more than 20 years of dedicated experience in R&D, manufacturing, and business related to syndromic real-time PCR technologies. This expertise was particularly highlighted during the COVID-19 pandemic when Seegene provided over 340 million COVID-19 tests to more than 100 countries worldwide. The core feature of Seegene’s syndromic real-time PCR technology is the ability to simultaneously test for 14 pathogens that cause similar symptoms in a single tube with quantitative information.<\/p>\n

Visit: <\/a>Seegene.com<\/a>\u00a0and follow <\/a>linkedin.com\/company\/seegene-inc<\/a><\/p>\n

\n<\/div>","protected":false},"excerpt":{"rendered":"

<\/p>\n\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

–\u00a0\u00a0\u00a0 Presented a roadmap to enhance screening reliability at the world’s leading multidisciplinary HPV congress held in Portugal<\/span> from March 16-19<\/span>
–\u00a0\u00a0\u00a0 Demonstrated how self-collected samples for HPV testing can bridge gaps in cervical cancer screening and advance HPV screening goals<\/p>\n

SEOUL, South Korea<\/span><\/span>, March 20, 2025<\/span><\/span> \/PRNewswire\/ — Seegene Inc., a global leader in total solution for PCR molecular diagnostics, presented its high-precision Human Papillomavirus (HPV) screening and full genotyping solutions at the European Research Organization on Genital Infection and Neoplasia (EUROGIN) 2025 in Porto, Portugal<\/span> from March 16-19<\/span>.<\/p>\n

\n

\"Seegene <\/a>
Seegene showcases its flagship HPV diagnostic product lineup and presents its HPV genotyping solution at EUROGIN 2025 in Portugal from March 16-19 (CET).<\/span><\/p>\n<\/div>\n

The company showcased its expertise through an exhibition booth under the theme “Elevating Confidence in HPV Screening” and hosted symposium programs to emphasize accurate identification of high-risk HPV types related to cervical cancer is critical. Seegene’s advanced solution enhances diagnostic accuracy, enabling timely and effective detection.<\/p>\n

Seegene presented its flagship HPV diagnostic product lineup that are designed to simultaneously detect HPV genotypes responsible for cervical cancer and\/or HPV-related cancer. This capability is crucial in identifying high-risk HPV types that are known to cause cervical cancer and detecting other genotypes that are associated with benign tumors.<\/p>\n

At the Seegene symposium on March 16<\/span>, leading clinical experts from Europe<\/span> discussed strategies for integrating HPV testing into real-world clinical practice. The symposium underscored the critical role of HPV testing in the early detection of cervical cancer. Additionally, the experts highlighted the advantages of self-sampling, a method that enables individuals to collect their own samples. This approach not only streamlines the testing process but also promotes the broader adoption of HPV screening.<\/p>\n

“Seegene’s HPV testing solutions are designed to deliver accurate diagnostics and reliable testing capabilities in real-world clinical environments,” said Daniel Shin<\/span>, Executive Vice President and Chief Global Sales & Marketing Officer at Seegene.<\/p>\n

Seegene’s annual participation in EUROGIN is a testament to its commitment to advancing HPV screening and genotyping for the accurate diagnosis and prevention of cervical cancer. In July 2024<\/span>, the company also took part in the Asia-Oceania Research Organization on Genital Infection and Neoplasia (AOGIN) 2024 held in Seoul<\/span>.<\/p>\n

According to the World Health Organization (WHO), Cervical cancer is the fourth most common cancer among women worldwide and the second leading cause of cancer-related deaths. In 2018, the WHO launched the 90-70-90 campaign to eliminate cervical cancer. The targets aim to achieve 90% HPV vaccination coverage among girls by the age of 15; 70% of women screened using high-performance tests by the age of 35 and 45; and treatment for 90% of women identified with pre-cancer and invasive cancer by 2030.<\/p>\n

About Seegene<\/b><\/p>\n

Seegene has more than 20 years of dedicated experience in R&D, manufacturing, and business related to syndromic real-time PCR technologies. This expertise was particularly highlighted during the COVID-19 pandemic when Seegene provided over 340 million COVID-19 tests to more than 100 countries worldwide. The core feature of Seegene’s syndromic real-time PCR technology is the ability to simultaneously test for 14 pathogens that cause similar symptoms in a single tube with quantitative information.<\/p>\n

Visit: <\/a>Seegene.com<\/a>\u00a0and follow <\/a>linkedin.com\/company\/seegene-inc<\/a><\/p>\n

\n<\/div>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-20262","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/20262","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20262"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/20262\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20262"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20262"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20262"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}